Insight Inv LLC Makes New Investment in Pfizer Inc. (NYSE:PFE)

Insight Inv LLC acquired a new stake in Pfizer Inc. (NYSE:PFEFree Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The firm acquired 9,340 shares of the biopharmaceutical company’s stock, valued at approximately $248,000.

A number of other institutional investors have also recently bought and sold shares of the business. AQR Capital Management LLC increased its position in shares of Pfizer by 1.6% during the second quarter. AQR Capital Management LLC now owns 612,429 shares of the biopharmaceutical company’s stock valued at $17,068,000 after buying an additional 9,435 shares during the period. Raab & Moskowitz Asset Management LLC increased its position in shares of Pfizer by 52.7% in the second quarter. Raab & Moskowitz Asset Management LLC now owns 238,937 shares of the biopharmaceutical company’s stock valued at $6,685,000 after acquiring an additional 82,497 shares during the period. MidWestOne Financial Group Inc. lifted its stake in Pfizer by 1.5% in the second quarter. MidWestOne Financial Group Inc. now owns 26,530 shares of the biopharmaceutical company’s stock worth $742,000 after acquiring an additional 386 shares during the period. Straight Path Wealth Management lifted its holdings in Pfizer by 21.3% in the second quarter. Straight Path Wealth Management now owns 37,025 shares of the biopharmaceutical company’s stock worth $1,036,000 after buying an additional 6,513 shares during the period. Finally, Ascent Group LLC boosted its position in shares of Pfizer by 23.2% during the second quarter. Ascent Group LLC now owns 50,845 shares of the biopharmaceutical company’s stock valued at $1,423,000 after purchasing an additional 9,565 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

PFE has been the topic of a number of analyst reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research report on Wednesday, October 23rd. Guggenheim reduced their price target on Pfizer from $35.00 to $33.00 and set a “buy” rating for the company in a report on Wednesday, December 11th. Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. Truist Financial reduced their price objective on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. Finally, UBS Group dropped their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer presently has an average rating of “Moderate Buy” and a consensus target price of $32.00.

Get Our Latest Report on PFE

Insider Activity

In other Pfizer news, Director Scott Gottlieb purchased 1,000 shares of the company’s stock in a transaction on Wednesday, October 30th. The stock was acquired at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the purchase, the director now directly owns 10,000 shares of the company’s stock, valued at $282,400. This trade represents a 11.11 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.06% of the company’s stock.

Pfizer Trading Down 1.3 %

Shares of Pfizer stock opened at $26.10 on Friday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The stock has a market capitalization of $147.89 billion, a PE ratio of 35.27, a P/E/G ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54. The company’s fifty day simple moving average is $26.11 and its 200-day simple moving average is $27.94.

Pfizer (NYSE:PFEGet Free Report) last posted its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The firm had revenue of $17.70 billion for the quarter, compared to analysts’ expectations of $14.92 billion. During the same period in the previous year, the firm earned ($0.17) EPS. The business’s quarterly revenue was up 31.2% on a year-over-year basis. As a group, equities analysts anticipate that Pfizer Inc. will post 2.94 earnings per share for the current year.

Pfizer Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, January 24th. This is a boost from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a yield of 6.59%. Pfizer’s dividend payout ratio (DPR) is currently 227.03%.

Pfizer Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Featured Stories

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.